Hemab Therapeutics closed a $157 million financing to advance a portfolio of clotting‑disorder programs, including two candidates already in clinical testing. The Series C was led by Sofinnova Partners and included crossover and strategic investors. The company said the proceeds will support a pivotal study start for sutacimig in Glanzmann thrombasthenia and further development of HMB‑002 after early proof‑of‑mechanism data. Hemab positions its pipeline to address multiple underserved bleeding disorders where commercial incentive has historically been limited. Management framed the round as capital to build “the ultimate coagulation disorders company” and to accelerate clinical milestones over the next 12–24 months.